Adial Pharmaceuticals' AD04 reduced heavy drinking days in AUD patients with specific genotypes in a Phase 3 study.
Adial Pharmaceuticals announced results of its Phase 3 ONWARD study showing that its lead asset, AD04 (low-dose ondansetron), reduced heavy drinking days among heavy drinking patients with Alcohol Use Disorder (AUD) and specific genotypic variants after six months of treatment. Adverse events were similar to placebo. The findings show promise for AD04 in precision medicine for AUD, potentially increasing demand for treatments.
June 20, 2024
4 Articles